In vitro antimalarial, antitrypanosomal and HIV-1 integrase inhibitory activities of two Cameroonian medicinal plants: *Antrocaryon klaineanum* (Anacardiaceae) and *Diospyros conocarpa* (Ebenaceae)

Y. Fouokeng [a], H.M. Feumo Feusso [a], J.E. Mbosso Teinkela [b,c,*], X. Siwe Noundou [d], R. Wintjens [c], M. Isaacs [e], H.C. Hoppe [e], R.W.M. Krause [d], A.G.B. Azebaze [a,**], J.C. Vardamides [a]

[a] Department of Chemistry, Faculty of Science, University of Douala,PO Box. 24157, Douala,Cameroon
[b] Département des Sciences Biologiques, Faculté de Médecine et des Sciences Pharmaceutiques (FMSP), Université de Douala,BP 2701 Douala, Cameroon
[c] Unité Microbiologie, Chimie Bioorganique et Macromoléculaire, Faculté de Pharmacie, Université Libre de Bruxelles (ULB), Campus Plaine (CP 206/4), Boulevard du Triomphe, 1050 Brussels, Belgium
[d] Nanomaterials and Medicinal Organic Chemistry Laboratory, Department of Chemistry, Faculty of Science, Rhodes University,PO Box 94, Grahamstown 6140, South Africa
[e] Department of Biochemistry and Microbiology, Rhodes University,PO Box 94, Grahamstown 6140, South Africa

A B S T R A C T

Antiplasmodial, antitrypanosomal and anti-HIV-1 activities of crude extracts, fractions and some isolated compounds from two Cameroonian medicinal plants: *Antrocaryon klaineanum* Pierre (Anacardiaceae) and *Diospyros conocarpa* Gürke ex K. Schum. (Ebenaceae) were assessed. The phytochemical studies led to the isolation of eight compounds (1–8) from *Diospyros conocarpa* and six compounds (6, 9–13) from *Antrocaryon klaineanum*. These compounds were identified as mangiferolic acid (1), 3β, 22(S)-dihydroxycycloart-24E-en-26-oic acid (2), lupeol (3), aridanin (4), betulin (5), betulinic acid (6), bergenin (7), D-quercitol(8), entilin C(9), entilin A(10), antrocarine A(11), 7R,20(S)-dihydroxy-4,24(28)-ergostadien-3-one(12) and stigmasterol glucoside (13). The criteria for activity were set as follows: an IC_{50} value < 10 μg/mL for crude extracts and < 1 μg/mL for pure compounds. The hexane/ethyl acetate (1:1) fraction of *A.klaineanum* root bark (AKERF1) and the hexane/ethyl acetate (1:1) fraction of *A. klaineanum* trunk bark (AKETF1) presented the strongest antiplasmodial activities with IC_{50} values of 0.4 and 4.4 μg/mL, respectively. Aridanin (4) and antrocarine A(11), as well as the crude extract of *D.conocarpa* roots (EDCR), AKERF1 and AKETF1 showed moderate trypanocidal effects. The crude extract of *A.klaineanum* root bark (AKER) and AKETF1 exhibited attractive activities on HIV-1 integrase with IC_{50} values of 1.96 and 24.04 μg/mL, respectively. The results provide baseline information on the use of *A.klaineanum* and *D.conocarpa* extracts, as well as certain components, as sources of new antiplasmodial, antitrypanosomal and anti-HIV drugs.

© 2018 SAAB. Published by Elsevier B.V. All rights reserved.

1. Introduction

Nowadays, parasitic diseases continue to be a threat to public health. In particular, two of these diseases cause serious mortality and morbidity in humans, the African trypanosomiasis or sleeping sickness, caused by *Trypanosoma brucei*, and the malaria, transmitted by *Plasmodium* species, of which the deadliest is *Plasmodium falciparum*. With the increase in the resistance of *P.falciparum* to several chemotherapeutic agents (Wellems and Plowe, 2001), malaria remains an important health concern in many countries, particularly in Africa.

Futhermore, acquired immunodeficiency syndrome (AIDS), caused by human immunodeficiency virus type-1 (HIV-1), is still a serious threat to public health, with more than 35 million people infected worldwide (WHO, 2017). The African continent, and more particularly sub-SaharanAfrica, is the most affected region, accounting for almost two thirds of the global total of new HIV-1 infections. In the fight against AIDS, inhibition of the HIV-1 integrase (IN) activity effectively suppresses virus replication, resulting in sustained clinical efficacy. However, only a few HIV-1IN inhibitors are currently approved for clinical use (Pandey and Grandgenett, 2008). Searching for other IN inhibitors from natural sources could be a useful approach (Suedee et al., 2014).

Indeed, plant biodiversity and knowledge of traditional healing can potentially open up new avenues in the field of drug discovery, as exemplified by the successful case of artemisinin. Here, we investigated the

activity of two Cameroonian plants selected based on ethno-botanical uses and bibliographical studies, namely *Antrocaryon klaineanum* Pierre (Anacardiaceae) and *Diospyros conocarpa* Gürke ex K. Schum. (Ebenaceae).

Antrocaryon klaineanum is recommended in traditional medicine to treat chlamydiae infections, wounds, back pain, liver diseases and female sterility (Betti, 2002; Matig et al., 2006). In Gabon, the powdered bark is used to cure liver complaints and to facilitate the production of breast milk, while the roots are used to treat abdominal and liver complaints (Kémeuzé and Nkongmeneck, 2011).

A chemical investigation of the stem bark of *A.klaineanum* was undertaken and resulted in the characterization of six new sterols (Douanla et al., 2015) and the isolation of two known compounds, 7,20S-dihydroxyergosta-4,24(28)-dien-3-one(Tchouankeu et al., 1996) and 20S-hydroxyergosta-4,6,24(28)-trien-3-one, described previously in the literature as a semi-synthetic product (Roy et al., 1982). The antiplasmodial assays of *A.klaineanum* crude extract and its isolated compounds were also reported (Douanla et al., 2015), and recently we purified and characterized eight compounds, resulting in the isolation of a new derivative (Fouokeng et al., 2017). Finally, *invitro* anti-HIV activity has also been reported for plants of Anacardiaceae family (*Rhus parviflora*, *Rhus succedanea…*) (Lin et al., 1997; Modi et al., 2013).

Plants of the genus *Diospyros* are used in traditional medicine for the treatment of several ailments such as leprosy, skin eruptions, eye infections, cough, fever, diarrhea, dysentery, malaria and skin diseases (Mallavadhani et al., 1998; Pathak et al., 2004; Ganapaty et al., 2006; Maridass, 2008; Sinha and Bansal, 2008; Sutthivaiyakit et al., 2012; Choi et al., 2015). This plant family is likewise used in the treatment of parasitic diseases, more especially those transmitted by protozoa (Freiburghaus et al., 1997; Mallavadhani et al., 1998; Bizimana et al., 2006; Norhayati et al., 2013).

Previous phytochemical studies on the genus *Diospyros* resulted in the isolation of various classes of secondary metabolites including triterpenes, naphthoquinones, coumarins and phenolic glycosides (Maridass, 2008; Sinha and Bansal, 2008). Limited information is known about the chemical constituents of *D.conocarpa*. Only seven compounds have been isolated and characterized from the stem bark of this plant (Feusso et al., 2016). Finally, in modern medicine various metabolites from *Diospyros* species have shown potent inhibitory activity against HIV-I protease, such as ursolic acid, whereas other compounds from this genus, such as beta-amyrin, betulin or diospyrin, exhibit moderate to potent cytotoxic actions on different carcinoma models (Sinha and Bansal, 2008).

In the present work, we carried out investigations on the antitrypanosomal, antimalarial and anti-HIV activities of the crude extract and isolated compounds from the two plants. In addition, cytotoxicity was evaluated to determine the selectivity/specificity of the plant samples.

2. Materials and methods

2.1. Plant materials

The trunk and root bark of *A.klaineanum* were collected on mount Eloumden in the central region of Cameroon in November 2014. The trunk and leaves of *D.conocarpa* were collected at Ntouessong in the central region in April 2013, whereas the roots were collected at Nkoemvone in the southern region in January 2015. The plant identification was carried out by the members of the National Herbarium of Cameroon, where voucher specimens were deposited (No 21247SRF/CAM and 24,030/SRF/CAM for *A. klaineanum* and *D.conocarpa*, respectively).

2.2. Extraction and isolation

2.2.1. Extraction and isolation from D.conocarpa

The different parts of *D.conocarpa* (leaves, trunk and roots) were air-dried at ambient temperature, then grounded and extracted at room

temperature with methanol for 48 h. The extracts were concentrated in a rotary evaporator to provide 210.8, 300.0, and 123.2 g of crude extracts from 1.6, 8.5 and 2.4 kg of leaves, trunk and roots, respectively. The total amounts of the three extracts were used for further separations and biological tests.

The leaf extract (EDCF) was separated by chromatography on silica gel eluted with a *n*-Hex, a *n*-Hex/EtOAc gradient of increasing polarity and finally MeOH to yield four fractions: **A**(5.01 g), **B**(94.8 g), **C**(7.4 g) and **D**(35.6 g). Non-polar fraction **A** and polar fractions **C** and **D** have not been studied here. Fraction **B** was further subjected to silica gel column chromatography eluted with an *n*-Hex/EtOAc gradient of increasing polarity. Elution with an *n*-Hex/EtOAc (7:1) gave **1**(30.0 mg) and with *n*-Hex/EtOAc (7:3) **2**(38.2 mg).

The trunk (EDCTr) and roots (EDCR) extracts were subjected to silica gel column chromatography eluted with a mixture of *n*-Hex/ EtOAc, pure ethyl acetate and a mixture of EtOAc/ MeOH. Elution of EDCTr extract with *n*-Hex/EtOAc (39:1) gave **3**(10.1 mg), and with EtOAc/ MeOH (19:1) gave **4**(30.2 mg). For the EDCR extract, elution with *n*-Hex/EtOAc (37:3) led to the isolation of **5**(9.4 mg) while **6**(12.5 mg) was isolated using *n*-Hex/EtOAc (9:1). Pure ethyl acetate was used to isolate **7**(23.5 mg) and **8**(918.0 mg) was isolated with EtOAc/MeOH (19:1).

2.2.2. Extraction and isolation from A.klaineanum

2.2.2.1. Extraction and isolation from trunk bark.
The air-dried and powdered trunk bark of *A.klaineanum* (AKET) (8.5 kg) was extracted twice with methanol at room temperature for 48 h. After evaporation with a rotary evaporator under reduced pressure at 40 °C, 833.4 g of crude extract was obtained and was fractionated using vacuum chromatography into fractions **A** [hexane/ethyl acetate (1:0 and 1:1), 84.5 g], **B** [ethyl acetate, 48.7 g] and **C** [methanol, 638.2 g]. Fractions **B** and **C** have not been studied yet.

Fraction **A** (AKETF1) (84.5 g) was subjected to silica gel column chromatography and eluted with a gradient system of *n*-hexane/ EtOAc (1:0 to 0:1); 475 sub-fractions(100 mL each) were collected and pooled on the basis of their TLC profile. Sub-fractions 32–101 obtained by eluting the column with *n*-hexane/EtOAc (97.5:2.5) afforded **9**(236.6 mg) and **10**(452.3 mg). Sub-fractions 102–205 (6.9 g) obtained by eluting the column with *n*-hexane/EtOAc (95:5 and 9:1) were further chromatographed on silica gel column and eluted with a gradient of *n*-hexane/EtOAc (0:1 to 8:2) to give **6**(237 mg). Elution with *n*-hexane/EtOAc (8:2) (232–254 sub-fractions) gave **11**(63 mg) and **12**(108 mg). Finally, **13**(104 mg) was obtained from sub-fractions 406–460 using elution with *n*-hexane/EtOAc (1:1).

2.2.2.2. Extraction and isolation from root bark.
The air-dried and powdered root bark of *A.klaineanum* (AKER) (7.5 kg) was extracted twice with methanol at room temperature for 48 h. After evaporation with a rotary evaporator under reduced pressure at 40 °C, 435.5 g of crude extract was obtained and was fractionated using vacuum chromatography into fractions **A** [hexane/ethyl acetate (1:0 and 1:1), 20.40 g], **B** [ethyl acetate, 170.35 g] and **C** [methanol, 180.25 g]. Only the fraction **A** (AKERF1) has been tested here.

2.3. Compound identification

The isolated compounds were characterized using various spectroscopic and spectrometric techniques such as 1D/2D-Nuclear Magnetic Resonance spectroscopy (NMR) and mass spectrometry (MS). The optical rotations were measured with a Perking–Elmer polarimeter (model 241) at the sodium D line ($\lambda = 589$ nm). Melting points were determined on a Melter FP61 melting point apparatus. The IR spectra were recorded on a FT/IR-4100 Jasco spectrometer. UV/Vis spectra were obtained on a Jasco V-650 spectrophotometer. The NMR spectra were recorded on a Varian Inova-600NMR spectrometer at 600 MHz (^{1}H NMR) or 150 MHz (^{13}C NMR). Chemical shifts were given in δ values

(ppm), and coupling constants are reported in [Hz]. HR-ESI mass spectra were obtained on a Bruker TOF LC–MS spectrometer. Open column chromatography was performed with silica gel (70–230 mesh). Thin-layer chromatography (TLC) was carried out on precoated silica gel 60 F254 plates (Merck), and the TLC spots were viewed at 254 nm and visualized by heating the plates at 80 °C for 10 min after spraying with 50% aqueous sulfuric acid.

2.4. Physico-chemical properties of isolated compounds

Mangiferolic acid(**1**): white powder, ESI-MS: [M-H]⁻ 455.4. ¹³C NMR: 32.0 C-1; 30.4 C-2; 77.4 C-3; 40.4 C-4; 47.1 C-5; 21.1 C-6; 26.0 C-7; 47.8 C-8; 19.7 C-9; 26.1 C-10; 26.3 C-11; 32.1 C-12; 45.3 C-13; 48.8 C-14; 35.4 C-15; 26.1 C-16; 52.6 C-17; 18.2 C-18; 29.7 C-19; 36.1 C-20; 19.4 C-21; 34.8 C-22; 25.9 C-23; 125.8 C-24; 146.1 C-25; 169.6 C-26; 12.6 C-27; 18.2 C-28; 14.5 C-29; 19.3 C-30. ¹H NMR(300 MHz; CDCl₃): 1.28 (m)H-1; 1.77 (m)H-2; 3.28 (m)H-3; 1.32 (m)H-5; 1.61 (m)H-6; 1.30 (m)H-7;H-8; 1.20 (m)H-11; 1.63 (m)H-12; 1.35 (m)H-15; 1.10 (m)H-16; 1.64 (m)H-17; 0.98 (s)H-18; 0.32 (d, J = 4.2); 0.56 (d, J = 4.2) H-19; 1.30 (m)H-20; 0.94 (d, J = 7.2) H-21; 1.60 (m)H-22; 1.37 (m)H-23; 6.89 (t, J = 6.6; 1.2) H-24; 1.81 (s)H-27; 0.63 (s)H-28; 0.83 (s)H-29; 0.98 (s)H-30.

3β,22(R)-dihydroxycycloart-24E-en-26-oic acid(**2**): white powder, ESI-MS: [M-H]⁻ 471.4. ¹³C NMR: 33.4 C-1; 31.3 C-2; 78.0 C-3; 41.1 C-4; 47.5 C-5; 21.5 C-6; 28.6 C-7; 48.1 C-8; 20.1 C-9; 26.2 C-10; 26.6 C-11; 32.9 C-12; 45.8 C-13; 49.2 C-14; 35.8 C-15; 26.3 C-16; 53.3 C-17; 19.6 C-18; 29.9 C-19; 44.1 C-20; 14.9 C-21; 65.8 C-22; 26.8 C-23; 127.3 C-24; 146.6 C-25; 170.8 C-26; 13.2 C-27; 18.4 C-28; 26.6 C-29; 26.2 C-30. ¹H NMR(300 MHz; CDCl₃): 1.28(m)H-1; 1.76 (m)H-2; 3.56 (m)H-3; 1.31 (m)H-5; 1.61 (m)H-6; 1.30 (m)H-7; 1.53 (m)H-8; 1.20 (m)H-11; 1.63 (m)H-12; 1.35 (m)H-15; 1.10 (m)H-16; 1.64 (m)H-17; 1.06 (s)H-18; 0.32 (d, J = 4.1); 0.58 (d, J = 4.1) H-19; 1.30 (m)H-20; 0.91 (d, J = 7.2) H-21; 4.98 (t, J = 3.7) H-22; 1.35 (m)H-23; 7.51 (d, J = 6.7) H-24; 2.08 (s)H-27; 1.11 (s)H-28; 0.98 (s)H-29; 1.04 (s)H-30.

Lupeol(**3**): white fiber, ESI-MS: [M + Na]⁺ 449.4. ¹³C NMR: 38.7 C-1; 27.4 C-2; 79.0 C-3; 38.8 C-4; 55.3 C-5; 18.3 C-6; 34.3 C-7; 40.8 C-8; 50.4 C-9; 37.1 C-10; 20.9 C-11; 25.1 C-12; 38.0 C-13; 42.8 C-14; 27.4 C-15; 35.6 C-16; 43.0 C-17; 48.0 C-18; 48.3 C-19; 151.6 C-20; 29.7 C-21; 40.0 C-22; 28.0 C-23; 15.3 C-24; 15.9 C-25; 16.1 C-26; 14.5 C-27; 18.0 C-28; 109.3 C-29; 19.3 C-30.

Aridanin(**4**): white powder, ESI-MS: [M-H]⁻ 658.5. ¹³C NMR: 38.6 C-1; 26.4 C-2; 89.2 C-3; 39.3 C-4; 55.8 C-5; 18.6 C-6; 33.2 C-7; 39.8 C-8; 48.0 C-9; 37.0 C-10; 23.7 C-11; 122.6 C-12; 144.8 C-13; 42.2 C-14; 28.3 C-15; 23.8 C-16; 46.7 C-17; 42.0 C-18; 46.5 C-19; 31.0 C-20; 34.3 C-21; 33.3 C-22; 28.2 C-23; 17.0 C-24; 15.4 C-25; 17.4 C-26; 26.2 C-27; 180.1 C-28; 33.3 C-29; 23.7 C-30; 104.8 C-1′; 58.2 C-2′; 76.1 C-3′; 72.8 C-4′; 78.2 C-5′; 63.1 C-6′. ¹H NMR (300 MHz; pyridin-d₅): 1.20 (m); 0.82 (t)H-1; 2.09 (m); 1.72 (m)H-2; 3.23 (m)H-3; 0.76 (s)H-5; 1.25 (m); 1.15 (m)H-6; 1.15 (m); 1.24 (m)H-7; 1.62 (t)H-9; 1.83 (d); 1.87 (d)H-11; 5.50 (sl) H-12; 2.07 (m)H-15; 2.04 (t)H-16; 3.23 (m)H-18; 1.15 (m); 1.82 (m)H-19; 1.12 (d); 1.24 (d)H-21; 1.82 (m); 2.00 (t)H-22; 1.11 (s)H-23; 0.98 (s)H-24; 0.76 (s)H-25; 0.97 (s)H-26; 1.15 (s)H-27; 0.95 (s)H-29; 1.01 (s)H-30; 5.04 (d, J = 8.2) H-1′; 4.26 (m) H-2′; 4.22 (t; J = 9) H-3′; 4.08 (t; J = 9 Hz) H-4′; 3.95 (m)H-5′; 4.18 (m); 4.38 (m)H-6′; 2.07 (s)OCH₃; 8.82 (d, J = 9) NHCOOCH₃.

Betulin(**5**): white powder, ESI-MS: [M + H]⁺ 443.4. ¹³C NMR: 38.8 C-1; 27.4 C-2; 79.0 C-3; 38.9 C-4; 55.3 C-5; 18.3 C-6; 34.3 C-7; 41.0 C-8; 50.4 C-9; 37.4 C-10; 20.9 C-11; 25.3 C-12; 37.2 C-13; 42.8 C-14; 27.1 C-15; 29.2 C-16; 47.8 C-17; 47.8 C-18; 48.8 C-19; 150.5 C-20; 29.8 C-21; 34.0 C-22; 28.0 C-23; 16.1 C-24; 16.3 C-25; 16.3 C-26; 16.1 C-27; 60.6 C-28; 109.7 C-29; 19.1 C-30.

Betulinic acid(**6**): white powder, ESI-MS: [M + Na]⁺ 479.4. ¹³C NMR: 39.0 C-1; 27.6 C-2; 78.2 C-3; 39.0 C-4; 55.5 C-5; 18.4 C-6; 34.5 C-7; 40.8 C-8; 50.7 C-9; 37.3 C-10; 21.0 C-11; 25.6 C-12; 38.2 C-13; 42.5 C-14; 30.4 C-15; 32.6 C-16; 56.3 C-17; 47.1 C-18; 49.4 C-19;

150.0 C-20; 29.9 C-21; 37.3 C-22; 27.9 C-23; 15.4 C-24; 16.2 C-25; 16.3 C-26; 14.6 C-27; 180.6 C-28; 108.8 C-29; 19.6 C-30.

Bergenin(**7**): colorless powder, ESI-MS: [M-H]⁻ 327.4. ¹³C NMR: 164.3 C-2; 119.5 C-3; 111.1 C-4; 152.7 C-5; 141.9 C-6; 149.3 C-7; 116.6 C-8; 73.9 C-9; 83.5 C-11; 72.1 C-12; 75.5 C-13; 81.3 C-14; 60.2 C-15; 62.6 C-16. ¹H NMR(300 MHz; pyridin-d₅): 7.75 (s)H-4; 5.12 (d, J = 10 Hz) H-9; 4.12 (s)H-11; 4.43 (t, J = 9.5; 10 Hz) H-12; 4.60 (t, J = 10.7; 2.5 Hz) H-13; 4.70 (dd, J = 9.5; 8.5 Hz) H-14; 3.96 (s)H-15; 4.09 (m)H-16.

D-quercitol(**8**): colorless powder, ESI-MS: [M-H]⁻ 163.4. ¹³C NMR: 69.0 C-1; 74.6 C-2; 71.1 C-3; 72.3 C-4; 68.6 C-5; 33.4 C-6. ¹H NMR(300 MHz; D₂O): 3.82 (m)H-1; 3.61 (t, J = 9.4 Hz) H-2; 3.82 (m) H-3; 3.98 (t, J = 3.1 Hz) H-4; 4.03 (t, J = 3.1 Hz) H-5; 1.88 (ddd; J = 3.0; 0.7; 13); 2.03 (dt, J = 2.6; 10.3) H-6.

Entilin C(**9**): White powder, HRESI-MS: [M + Na]⁺ 511.2 (calculated for C₂₇H₃₆O₈, 488.24102). ¹H NMR(300 MHz, CDCl₃): 3.76 (1H; d;1.7) H-3; 5.28 (1H, t, 1.6) H-5; 1,87; 1,97 (2H; t)H-11; 1.48 (2H, m)H-12; 2.03 (1H, t, 3.3) H-14; 1,91; 2.00 (2H, t)H-15; 5.50 (H, s)H-17 0.79 (3H, s)H-18; 1.83 (3H, s, 1.5) H-19; 7.33 (1H, s)H-21; 6.33 (1H, d, 1.8) H-22; 7.40 (1H, d, 1.70) H-23; 1.07 (3H, s)H-28; 1.16 (3H, s)H-29; 4.60 (1H, s)H-30; 1.91 (1H, m)H-2′; 1.01 (3H, d, 7.0) H-3′; 1.03 (3H, d; 7.0) H-4′; 3.59 (1H, s)1-OH; 2.93 (1H, s)2-OH; 3.42 (3H, s)9-OMe.

Entilin A(**10**): White powder, HRESI-MS: [M + Na]⁺ 488,24,102 (calculated for C₂₈H₄₄O₈, 414.33932) ¹³C NMR(75 MHz, CDCl₃): 98.8 C-1; 76.7 C-2; 81.0 C-3; 38.1 C-4; 133.8 C-5; 79.7 C-8; 97.6 C-9; 127.6 C-10; 30.9 C-11; 32.2 C-12; 35.4 C-13; 38.3 C-14; 22.6 C-15; 72.7 C-17; 24.5 C-18; 16.5 C-19; 124.4 C-20; 139.5 C-21; 10.6 C-22; 143.5 C-23; 27.8 C-28; 27.9 C-29; 30.9 C-30; 38.8 C-1′; 16.9 C-2′; 17.0 C-4′. ¹H NMR(300 MHz, CDCl₃): 3.76 (1H; d;1.7) H-3; 5,23 (1H; t; 1,6) H-5; 1,87; 1,97 (2H; t)H-11; 1.48 (2H, m)H-12; 2.03 (1H, t, 3.3) H-14; 1,91; 2.00 (2H, t)H-15; 0.79 (3H, s)H-18; 1.83 (3H, s, 1,5) H-19; 7.28 (1H, s) H-21; 6.29 (1H, dd, 1.8) H-22; 7.35 (1H, d, 1.71) H-23; 1.07 (3H, s)H-28; 1.16 (3H, s)H-29; 4.60 (1H, s)H-30; 1.91 (1H, m)H-2′; 1.01 (3H, d, 7.0) H-3′; 1.03 (3H, d; 7.0) H-4′; 3.59 (1H, s)1-OH; 2.93 (1H, s)2-OH; 3.28 (1H, s)9-OH.

Antrocarine A(**11**): White powder, ESI-MS: [M + Na]⁺ 451.4 (calculated for C₂₉H₄₈O₂) ¹³C NMR(75 MHz, CDCl₃): 37.1 C-1; 31.4 C-2; 42.1 C-3; 123.9 C-4; 146.3 C-5; 65.4 C-6; 71.4 C-7; 37.6 C-8; 42.3 C-9; 37.4 C-10; 20.8 C-11; 39.2 C-12; 42.2 C-13; 49.5 C-14; 24.3 C-15; 28.3 C-16; 55.7 C-17; 11.7 C-18; 18.3 C-19; 35.8 C-20; 18.8 C-21; 24.8 C-22; 30.9 C-23; 156.9 C-24; 33.8 C-25; 22.0 C-26; 21.9 C-27; 106.6 C-28. ¹H NMR(300 MHz, CDCl₃) (σ (ppm), m, J(Hz)): 1.51, 1.91 (2H, t) H-1; 1.85, 1.93 (2H q)H-2; 2.32, 2.42(2H, m)H-3; 5.65, (1H, dd, (8, 5.4)) H-4; 3.91 (s, br) H-6; 3.91 (1H, d)H-6; 3.62 (1H, m)H-7 1.17 (1H, t)H-8; 1.35 (1H, t) H-9; 1.54; 1.61 (2H, q) H-11; 2.02; 2.1 (2H, t) H-12; 1.50 (1H, t)H-14; 1.74; 1.83 (2H, q)H-15; 1.38, 1.97 (2H, t)H-16; 1.26 (1H, t)H-17; 0.73 (3H, s)H-18; 1.05 (3H, s)H-19; 1.58 (1H, q) H-20; 0.99 (3H, d, 6.6) H-21; 1.65, 2.24 (2H, q)H-22; 2.13, 2.21(1H, d)H-23; 2.31(1H, m)H-25; 1.07 (3H, d, 6.6) H-26; 1.05 (3H, d, 6.6) H-27; 4.71; 4.78 (2H, d, 1.5) H-28.

7α,20(S)-dihydroxy-4,24(28)-ergostadien-3-one(**12**): white powder, ESI-MS: [M + Na + 2H] ⁺m/z = 437.3 (calculated for C₂₈H₄₄O₂ (413.3407)) ¹³C NMR(75 MHz, CDCl₃): 35.3 C-1; 33.8C-2; 199.0 C-3; 127.8 C-4; 168.1 C-5; 41.0 C-6; 68.5 C-7; 39.0 C-8; 44.9 C-9; 38.4 C-10; 20.6 C-11; 39.5 C-12; 42.6 C-13; 50.5.5 C-14; 23.0 C-15; 22.3C-16; 57.7 C-17; 13.4 C-18; 19.9C-19; 75.0 C-20; 26.2 C-21; 42.4 C-22; 23.9 C-23; 156.1C-24; 33.9 C-25; 21.9 C-26; 21.9 C-27; 106.2 C-28. ¹H NMR(300 MHz, CDCl₃) (σ (ppm), m, J(Hz)): 1.75, 2.02, (2H, t), H-1; (2.36 (2H, q)H-2; 5.77, (1H, s)H-4; 2.40, 2.60 (1H, m)H-6; 3.95 (1H, q, 3.1) H-7; 1.55 (1H, m)H-8; 1.44 (1H, m) H-9; 1.44; 1.55(2H, m)H-11; 2.00 (2H, m)H-12; 1.36 (1H, m)H-14; 1.69 (2H, m)H-15; 1.90; 1.30 (2H, m)H-16; 1.118 (1H, m)H-17; 0.69 (3H,s) H-18; 1.27 (3H, s)H-19; 1.40 (1H, m)H-20; 0.93 (3H, d, 6.2) H-21; 1.15, 1.52(2H, m)H-22; 2.06, 1.87 (2H, m)H-23; 2.20 (1H, m)H-25; 1.00 (3H, d, 6.9)H-26; 0.99 (3H, d, 6.9) H-27; 4.69 4.78 (2H, d, 1.5) H-28.

β-sitosterol glucoside(**13**): Beige powder, Tf: 257–258 °C; ESI-MS: [M + Na + 2H] $^+$ m/z = 599.4 (calculated for $C_{35}H_{60}O_6Na$ (599.4255) ^{13}C NMR(75 MHz, CDCl₃): 38. 5 C-1; 33.5 C-2; 77.1 C-3; 37.0 C-4; 140.5 C-5; 121.3 C-6; 31.5 C-7; 31.6 C-8; 49.8 C-9; 36.4 C-10; 22.7 C-11; 41.9 C-12; 42.0 C-13; 56.2 C-14; 25.0 C-15; 28.8 C-16; 55.5 C-17; 11.8 C-18; 19.3 C-19; 35.6 C-20; 18.8 C-21; 138.1 C-22; 129.0 C-23; 50.7 C-24; 24.0 C-25; 12.0 C-26; 29.4 C-27; 20.7 C-28; 100.9 C-1′; 73.5 C-2′; 77.1 C-3′; 70.2 C-4′; 76.9 C-5′; 61.2 C-6′. ^1H NMR(300 MHz, CDCl₃) (σ (ppm), m, J(Hz)): 1.24 (2H, m)H-1; (1.39 (2H, m)H-2; 1.93 (2H, dd) H-4; 5.32 (1H, dd) H-6; 1.80 (2H, m)H-7;) 1.50 (1H, m)H-8; 1.50 (1H, m)H-9; 1.50(2H, m)H-11; 1.50 (2H, m)H-12; 1.15 (1H, m) H-14; 1.80 (2H, m)H-15; 1.80 (2H, m)H-16; 1.24(1H) H-17; 0.82 (3H, s) H-18; 0.95 (3H, s)H-19; 2.12 (1H, dd) H-20; 0.90 (3H, d)H-21; 5.16 (1H, d)H-22; 5.03 (1H, m)H-23; 1.15 (2H, m)H-25; 1.50 (3H, H-26; 1.63 (1H, m)H-27; 0.76 (3H, dd) H-28; 0.99 (3H, d)H-29; 4.22 (d)H-1′; 2.90 (m)H-2′; 3.12 (m)H-3′; 3.06 (dd) H-4′; 3.02 (dd) H-5′; 3.64 (dd) H-6′ 4.86 (t)2′-OH; 4.89 (d)3′-OH; 4.86 (t)4′-OH; 4.42 (t)6′-OH.

2.5. Antiplasmodial activity

Activity against *Plasmodium falciparum*chloroquine-sensitive 3D7 strain was assessed following a procedure already described (Desjardins et al., 1979). Malaria parasites were maintained in RPMI 1640 medium containing 2 mM L-glutamine and 25 mM Hepes (Lonza). The medium was further supplemented with 5% Albumax II,20 mM glucose, 0.65 mM hypoxanthine, 60 μg/mL gentamycin and 2–4% hematocrit human red blood cells. The parasites were cultured at 37 °C under an atmosphere of 5% CO_2, 5% O_2, 90% N_2 in sealed T25 or T75 culture flasks. For screening samples against malaria parasites, a compound or natural extract was added to parasite cultures in 96-well plates and incubated for 48 h in a 37 °C CO_2 incubator. After 48 h, the culture plates were taken out from the incubator. Then, 20 μL of culture were removed from each well and mixed in a fresh 96-well plate with 125 μL of a mixture of Malstat solution and NBT/PES solution. The parasite lactate dehydrogenase (pLDH) activity was measured in these solutions. A purple product was formed when pLDH was present, and this product could be quantified by absorbance at 620 nm (Abs_{620}). The Abs_{620} reading in each well was thus an indication of the pLDH activity and thereby of the number of parasites in the well.

2.6. Antitrypanosomal activity

To assess antitrypanocidal activity, *invitro* cultures of *Trypanosoma brucei brucei* in 96-well plates were carried out. After an incubation period of 48 h, the number of parasites surviving drug exposure was determined by adding a resazurin-based reagent. Resazurin is reduced to resorufin by living cells. Resorufin is a fluorophore (Excitation$_{560}$/Emission$_{590}$) and can be quantified in a multi-well fluorescence plate reader.

2.7. HIV-1 integrase strand transfer reaction assay

The HIV-1 subtype C integrase (CIN) strand transfer inhibition assay was adapted from a previously described method (Grobler et al., 2002). Briefly, 20 nM double-stranded biotinylated donor DNA (5′-5 Biotin TEG/ACCCTTTTAGTCAGTGTGGAAAATCTCTAGCA-3′ annealed to 5′-ACTGCTAGAGATTTTCCACACTGACTAAAAG-3′) was immobilized in streptavidin coated 96-well microtiter plates (R&D Systems, USA). Following incubation at room temperature for 40 min and, as stringent wash step, 5 μg/mL purified recombinant HIV-1CIN in buffer 1 (50 mm NaCl, 25 mM Hepes, 25 mM MnCl₂, 5 mM β-mercaptoethanol, 50 μg/ mL BSA,pH 7.5) was added to individual wells. Recombinant HIV-1CIN was assembled onto the pre-processed donor DNA through incubation for 45 min at room temperature. Strand transfer reaction was initiated through the addition of 10 nM (final concentration) double-strandedFITC-labeled target DNA (5′-TGACCAAGGGCTAATTCACT/36-FAM/−3′ annealed to 5′-AGTGAATTAGCCCTTGGTCA−/36-FAM/−3′)

in integrase buffer 2 (same as buffer 1, except 25 mm MnCl₂ replaced with 2.5 mm MgCl₂). After an incubation period of 60 min at 37 °C, the plates were washed using PBS containing 0.05% Tween 20 and 0.01% BSA, followed by the addition of peroxidase-conjugated sheep anti-FITC antibody (Thermo Scientific, USA) diluted 1:1000 in the same PBS buffer. Finally, the plates were washed and peroxidase substrate (Sure Blue Reserve™, KPL, USA) was added to allow for detection at 620 nm using a Synergy MX (BioTek®) plate reader. Absorbance values were converted to percentage of enzyme activity relative to the readings obtained from control wells (enzyme without inhibitor).

2.8. Cytotoxic activity

To assess the overt cytotoxicity, plant samples were incubated for 24 h, at a concentration of 20 μM (for pure compounds) or 25 μg/mL (for extracts) in 96-well plates containing HeLa cells (human cervix adenocarcinoma), maintained in a culture medium made of Dulbecco's Modified Eagle's Medium with 5 mM L-glutamine (Lonza), supplemented with 10% fetal bovine serum and antibiotics (penicillin/streptomycin/fungizone – PSF). The number of cells surviving drug exposure was evaluated using the resazurin based reagent and resorufin fluorescence quantified (Excitation$_{560}$/Emission$_{590}$) in a multi-well plate reader.

2.9. Single concentration screening

The percent of parasitemia, or cell viability, was calculated at a fixed concentration of 20 μM for isolated compounds or 25 μg/mL for natural plant extracts. Experiments were performed in triplicate wells and a standard deviation was derived. For comparative purposes, chloroquine (an anti-malarial drug), emetine (which induced cell apoptosis) or pentamidine (an existing drug used in the treatment of trypanosomiasis) were used as positive control drug standards at a concentration of 10 μM for the two first drug or of 1 μM in case of pentamidine. Compounds were tested for HIV-1 integrase at a concentration of 20 μM (pure compounds) and 25 μg/mL (crudes extracts) and chicoric acid was used as positive control for HIV-1 integrase at a concentration of 20 μM.

2.10. Dose response

The IC$_{50}$ (50% inhibitory concentration) of tested extract/compound exhibiting a low percentage viability was determined from the resulting dose–response curve by non-linear regression using the Prism 5 program (Version 5.02, graph Pad Software, Inc). Chloroquine and pentamidine were used as drug standards according to the type of test performed. IC$_{50}$ values for cytotoxicity were not determined due to the low inhibition observed by the preliminary single concentration screening (see Results). Extracts and isolated compounds were tested in a concentration range from 100 to 0.045 μg/mL or μM respectively using 3-fold serial dilutions for antiplasmodial tests and from 100 to 0.00001 μg/mL or μM respectively, with 10-fold serial dilutions for antitrypanosomal assays.

3. Results and discussion

3.1. Phytochemistry study

The different crude extracts of *D.conocarpa* (EDCR, EDCF and EDCTr) were extracted by silica gel column chromatography and preparative TLC, resulting in the isolation and characterization of eight pure compounds: mangiferolic acid (**1**), 3β,22(R)-dihydroxycycloart-24E-en-26-oic acid (**2**) (Anjaneyulu et al., 1999), lupeol (**3**) (Prachayasittikul et al., 2010), aridanin (**4**) (Adesina and Reisch, 1985), betulin (**5**) (Prachayasittikul et al., 2010), betulinic acid (**6**) (Yili et al., 2009),

Fig. 1. Chemical structures of compounds isolated from leaves, stems, and roots of *D.conocarpa*.

bergenin (**7**) (Nunomura et al., 2009) and D-quercitol(**8**) (Venkateswara Rao et al., 2014) (Fig. 1).

The n-hexane/ethyl acetate (1:1) fraction (AKETF1), obtained by chromatography on the crude extract of *A.klaineanum* trunk bark, was separated by chromatography on silica gel column and thin-layer plates. Six pure compounds were isolated and identified, namely entilin C(**9**) (Daniewski et al., 1994), entilin A(**10**) (Tchouankeu et al., 1990), betulinic acid (**6**) (Yili et al., 2009), antrocarine A(**11**) (Douanla et al., 2015), 7α,20(*S*)-dihydroxy-4,24(28)-ergostadien-3-one (**12**) (Tchouankeu et al., 1996) and β-sitosterol glucoside (**13**) (Yili et al., 2009) (Fig. 2).

3.2. Antiplasmodial activity

The two crude extracts of *A.klaineanum* [AKET (crude extract of trunk bark of *A.klaineanum*) and AKER (crude extract of stem bark of *A.klaineanum*)] did not reduce significantly the viability of the parasite whereas AKERF1 [hexane/EtOAc (1:1) fraction of crude extract of root bark of *A.klaineanum*] and AKETF1 [hexane/EtOAc (1:1) fraction of crude extract of trunk bark of *A.klaineanum*] fractions showed the best antiplasmodial activities with IC_{50} values of 0.44 and 4.43 μg/mL, respectively, compared with chloroquine which was used here as a drug reference (IC_{50}0.009 μM). No pure compounds significantly reduced


Fig. 2. Chemical structures of compounds isolated from trunk bark of *A.klaineanum*.

the viability of the parasite (Table 1). The low activity of *A.klaineanum* crude extracts could be due to the presence of compounds having antagonistic effects, while the antiplasmodial activity of fractions AKERF1 and AKETF1 suggests that the compounds contained in these fractions might be acting in synergy (Chithambo et al., 2017). In another study, the crude extract of *A.klaineanum* stem bark also showed moderate antiplasmodial activity with an IC_{50} value of 16.7 μg/mL on the 3D7 *P.falciparum* strains (Douanla et al., 2015).

For crude extracts, IC_{50} values below 100 μg/mL were proposed as endpoint criteria in anti-infective assays (Cos et al., 2006), although the most promising antimalarial extracts exhibit IC_{50} values under 10 μg/mL (Soh and Benoit-Vical, 2007; Krettli, 2009). Hence, as the hexane/EtOAc (1:1) fraction AKERF1 exhibited an IC_{50} value lower than 1 μg/mL against *P.falciparum*, this fraction represented undoubtedly a good candidate for further bioassay-guided fractionation. Finally, taken together, all the results support the use of the bark of *A. klaineanum* in traditional medicines for treating malaria (Matig et al., 2006; Betti and Lejoly, 2010; Douanla et al., 2015).

The crude extracts of *D.conocarpa* roots and trunk [EDCR (crude extract of roots of *Diospyros conocarpa*) and EDCTr (crude extract of trunk of *Diospyros conocarpa*)], as well as the isolated compounds, showed low activities against *P.falciparum* strains with viability percentages (PVs) consistently greater than 90%. This is in contrast with the ethyl acetate extract of *Diospyros hispida* roots which displayed growth inhibitory activity with an IC_{50} value of 1 μg/mL against *P.falciparum* (Albernaz et al., 2010). According to the literature, the roots, barks, heartwood and stems of some *Diospyros* species are used in traditional medicine to treat malaria (Kantamreddi and Wright, 2008; Mohamed et al., 2009; Prachayasittikul et al., 2010) but no antimalarial activity

has yet been reported for *D.conocarpa*. Due to the low level of activity, its traditional use as antimalarial might not be ascribed to the extracts tested in our study.

3.3. Antitrypanosomal activity

According to the traditional pharmacopeia, the trunk bark of *A. klaineanum* has antiparasitic activity. Besides the antiplasmodial activity described in the previous section, we proposed to assay the antitrypanosomal activity of this plant, in particular as some related species, such as *Magnifera indica* and *Spondias mombim*, exhibit antitrypanosomal effects (Nwodo et al., 2015).

The results showed that the three crude extracts, AKER, AKET and EDCTr, as well as the fraction AKERF1, exhibited moderate activities, with PVs of 26.75, 43.96, 52.42 and 4.48, respectively (Table 1). The fraction AKETF1 displayed an antitrypanosomal activity with an IC_{50} value between 10 and 1 μg/mL. Aridanin (**4**) and antrocarine A(**11**) exhibited trypanocidal activities on the *T.b. brucei* strain with IC_{50} values of 10–1 and 8.9 μM, respectively.

The two crude extracts, AKER and AKET, were less active than their related fractions AKERF1 and AKETF1. This could be due to the presence of compounds having antagonistic effects (Zhu et al., 1997). However, the strong activity of the antrocarine A(**11**), which is the major compound isolated from the fraction AKETF1, sustains the trypanocidal effect of this latter fraction (Table 1). The antitrypanosomal activity of aridanin (**4**) (PV = 0.59 ± 0.08) was comparable to that of the extract EDCR (PV = 1.04 ± 0.18), from which the compound was extracted (Table 1). These results confirm the use of the plant extracts of *Diospyros* genus in the treatment of parasitic diseases, more especially those

Table 1
In vitro assays of the extracts and compounds.

Sample		Antimalarial activity[a]		Antitrypanosomal activity[b]		Cytotoxic activity[c]		HIV-1 CIN activity[d]	
Name	Code	PV (%)	IC_{50}	PV (%)	IC_{50}	PV (%)	IC_{50}	% Activity	IC_{50}
Extract									
Crude extract of trunk bark of AK	AKET	132.28 ± 18.06	nd	43.96 ± 7.97	nd	90.30 ± 12.74	nd	38.87	17.39
Crude extract of roots bark of AK	AKER	82.57 ± 4.48	nd	26.75 ± 3.82	nd	100.32 ± 2.08	nd	−43.90	1.96
Crude extract of roots of DC	EDCR	90.49 ± 5.64	nd	1.04 ± 0.18	nd	95.60 ± 13.59	nd	105.64	nd
Crude extract of Trunk of DC	EDCTr	90.81 ± 2.72	nd	52.42 ± 8.20	nd	48.50 ± 8.88	nd	43.14	24.04
Hexane/EtOAc (1:1) fraction of AKET	AKETF1	-5.41 ± 2.13	4.43	2.15 ± 0.48	10–1	61.60 ± 7.04	nd	−26.98	3.60
Hexane/EtOAc (1:1) fraction of AKER	AKERF1	-13.61 ± 3.01	0.44	4.48 ± 0.67	nd	88.85 ± 3.61	nd	−18.45	35.08
Compound									
Mangiferonic acid	**1**	90.72 ± 5.73	nd	98.48 ± 9.31	nd	87.65 ± 4.88	nd	126.98	nd
3β, 22(R ou S)-dihydroxycycloart 24E-en-26-oic acid	**2**	82.24 ± 17.11	nd	53.48 ± 4.22	nd	78.53 ± 12.19	nd	220.88	nd
Lupeol	**3**	108.93 ± 10.00	nd	51.32 ± 7.36	nd	88.48 ± 2.43	nd	96.95	
Aridanin	**4**	80.40 ± 5.88	nd	0.59 ± 0.08	10–1	76.04 ± 3.58	nd	85.52	18.32
Betulin	**5**	105.01 ± 8.71	nd	58.86 ± 10.75	nd				
Betulinic acid	**6**	100.48 ± 10.57	nd	93.68 ± 3.40	nd	73.92 ± 0.30	nd	14.02	nd
Bergenin	**7**	101.15 ± 0.78	nd	98.36 ± 4.27	nd	68.00 ± 16.15	nd	158.23	nd
D-quercitol	**8**	101.54 ± 7.34	nd	95.77 ± 7.87	nd	82.72 ± 13.48	nd	257.32	nd
Entiline C	**9**	106.60 ± 1.83	nd	103.92 ± 7.53	nd	83.50 ± 7.09	nd	174.24	nd
Entiline A	**10**	117.98 ± 0.29	nd	36.61 ± 0.22	nd	83.53 ± 3.43	nd	253.81	nd
Antrocarine A	**11**	120.02 ± 7.89	nd	2.29 ± 0.18	8.92	97.33 ± 0.21	nd	207.47	nd
7R, 20(S)-dihydroxy-4,24(28)-ergostadien-3-one	**12**	123.84 ± 9.51	nd	95.36 ± 3.56	nd	104.22 ± 0.30	nd	143.75	nd
Stigmasterol glucosid	**13**	113.13 ± 7.24	nd	72.41 ± 6.27	nd	81.12 ± 8.10	nd	59.15	nd
References									
	Chloroquine	−5.60	0.0089						
	Pentamidine				0.00078				
	Emetine						0.044		
	Chicoric acid							−51.37	0.008

PV values are from two replicate experiments 20 μM (pure compound) or 25 μg/mL (plant extract);
AK: *Antrocaryon klaineanum*, DC: *Diospyros conocarpa*, nd: not determined;
PV: percentage viability;
IC_{50}: 50% inhibitory concentration, *i.e.* the concentration of extract/compound that reduces by 50% the growth or proliferation of cells in μg/mL for extracts and fractions, and in μM for pure compounds and reference drugs.
  [a] *P.falciparum* 3D7 strain;
  [b] *T.brucei brucei* strain trypomastigotes;
  [c] HeLa (human cervix adenocarcinoma) cells;
  [d] HIV-1 integrase inhibitory activity;

Y. Fouokeng et al. / South African Journal of Botany 122 (2019) 510–517

transmitted by protozoa (Freiburghaus et al., 1997; Mallavadhani et al., 1998; Bizimana et al., 2006; Norhayati et al., 2013).

3.4. Cytotoxic activity

The crude extracts, some fractions and the pure compounds were tested against HeLa cells. As the percentages of cell viability remained high (>48%) for all tested samples, the IC_{50} values were not assessed. Hence, all the samples were non-cytotoxic against HeLa cervical cancer cells.

3.5. HIV-1 Integrase inhibitory activity

The results showed that all crude extracts except EDCR exhibited moderate HIV-1IN inhibitory activity with IC_{50} values of 24.04, 17.39 and 1.96 μg/mL for EDCTr, AKET and AKER, respectively (Table 1). The fractions AKERF1 and AKETF1 also displayed a moderate HIV-1IN inhibitory action with IC_{50} values of 35.08 and 3.60 μg/mL, respectively, compared with chicoric acid taken as a reference drug (IC_{50} 0.008 μM). Among the pure compounds tested, only aridanin (**4**) presented a moderate activity with an IC_{50} of 18.32 μM (Table 1).

According to phytochemical screening studies, the *A.klaineanum* methanol extract contains steroids, flavonoids, tannins and phenolic compounds (Sima et al., 2015; Fongang et al., 2017). Some *Anarcadiaceae* species, such as *Spondias speciosa*, *Mangifera indica* and *Rhuspar viflora*, exhibited anti-HIV-1 effects (Guha et al., 1996; Sahar et al., 2009; Modi et al., 2013).

The HIV-1 inhibitory activity observed for aridanin (**4**) (IC_{50} 18.32 μM) corroborated the effects of the EDCTr extract (IC_{50} 24.04 μg/mL). However, the crude extract of *D.Conocarpa* roots (EDCR) exhibited no significant activity with a PV of 105.64. The same trend was observed for lupeol (**3**), betulin (**5**) and betulinic acid (**6**) with PV of 96.95, 95.58 and 85.52, respectively. These later compounds are pentacyclic triterpenes belonging to the lupane serie. According to the literature, betulinic acid and its derivatives have been reported to inhibit HIV-1 entry and replication, HIV protease or the HIV reverse transcriptase (Fujioka and Kashiwanda, 1994; Mayaux et al., 1994; Pengsuparp et al., 1994; Xu et al., 1996; Dzubak et al., 2006). HIV-1IN inhibitory activities were reported for the wood of *D.decandra*, the bark of *D.rhodocalyx* Kurz, the leaves of *D.chloroxylon* Roxb. and *D.Montana* Roxb. (Sahar et al., 2009; Bunluepuech and Tewtrakul, 2009, 2011). Such activity was found here for the first time in plant extracts of *D.conocarpa* and *A. klaineanum*.

4. Conclusion

The *invitro* antimalarial, antitrypanosomal and HIV-1 inhibitory integrase activities were assessed for different extracts of two Cameroonian plants. Interestingly, the performed extractions led to the isolation and the identification of 13 different chemical compounds that were additionally tested for their *invitro* activities. Although all these compounds have already been isolated from other plants, we clearly established here their presence in the different extracts of *A. klaineanum* and *D.conocarpa*.

The *A.klaineanum* hexane/EtOAc (1:1) fractions of root and trunk barks, AKERF1 and AKETF1, showed the best antiplasmodial activities whereas on the contrary the corresponding crude extracts did not significantly decrease the viability of the parasite *P.falciparum*. The presence of chemicals with antagonistic effects in crude extracts could explain these results. In marked contrast, it was found that *D.conocarpa* extracts of roots and trunk, as well as all isolated compounds, had only little effects against *P.falciparum* growth. Therefore, the observed activities of AKERF1 and AKETF1 could result from synergetic action of chemicals or phytocomplexes present in these fractions. Furthermore, according our results the traditional use *D.conocarpa* as antimalarial

would not be assigned to the two plant parts tested, but more likely to other parts of the plant.

The crude extract EDCR of *D.conocarpa*, fractions AKERF1 and AKETF1, as well as isolated compounds aridanin (**4**) and antrocarine A(**11**), all presented moderate trypanocidal activity, confirming thereby the antiprotozoal potential of *Antrocaryon* and *Diospyros* genus. In addition, the comparison between the parasiticidal and cytotoxicity effects suggests that the decrease in viability of parasites may not be caused by a general cytotoxicity of the tested extracts. Concerning the anti-HIV potential of the plants, it is worthy of note that the AKER and AKETF1 fractions of *A.klaineanum* exhibited attractive inhibitory activity against HIV integrase. Finally, further studies are therefore necessary to determine putative new antiplasmodial, antitrypanosomal and/or anti-HIV agents for drug preparation.

Competing interest

The authors declare no conflict of interest.

References

Adesina, S.K., Reisch, J., 1985. A triterpenoid glycoside from *Tetrapleura tetraptera* fruit. Phytochemistry 24, 3003–3006.

Albernaz, L.C., de Paula, J.E., Romero, G.A.S., Silva, M. do R.R., Grellier, P., Mambu, L., Espindola, L.S., 2010. Investigation of plant extracts in traditional medicine of the Brazilian Cerrado against protozoans and yeasts. Journal of Ethnopharmacology 131, 116–121.

Anjaneyulu, V., Satyanarayana, P., Viswanadham, K.N., Jyothi, V.G., Rao, K.N., Radhika, P., 1999. Triterpenoids from *Mangifera indica*. Phytochemistry 50, 1229–1236.

Betti, J.L., 2002. Medicinal plants sold in Younde markets Cameroon. African Study Monographs 23, 47–64.

Betti, J.-L., Lejoly, J., 2010. Contribution à la connaissance des plantes médicinales de la réserve de biosphère du Dja au Cameroun : Plantes utilisées dans le traitement des maux de dos. International Journal of Biological and Chemical Sciences 4, 193–200.

Bizimana, N., Tietjen, U., Zessin, K.H., Diallo, D., Djibril, C., Melzig, M.F., Clausen, P.H., 2006. Evaluation of medicinal plants from Mali for their *invitro* and *invivo* trypanocidal activity. Journal of Ethnopharmacology 103, 350–356.

Bunluepuech, K., Tewtrakul, S., 2009. Anti -HIV-1 integrase activity of Thai Medicinal Plants. Songklanakarin. Journal of Science and Technology 31, 289–292.

Bunluepuech, K., Tewtrakul, S., 2011. Anti-HIV-1 integrase activity of Thai medicinal plants in longevity preparations. Songklanakarin. Journal of Science and Technology 33, 693–697.

Chithambo, B., Noundou, X.S., Krause, R.W.M., 2017. Anti-malarial synergy of secondary metabolites from *Morinda lucida* Benth. Journal of Ethnopharmacology 199, 91–96.

Choi, J., Cho, J.Y., Kim, Y.D., Htwe, K.M., Lee, W.S., Lee, J.C., Kim, J., Yoon, K.D., 2015. Phenolic compounds and triterpenes from the barks of *Diospyros burmanica*. Natural Product Sciences 21, 76–81.

Cos, P., Vlietinck, A.J., Berghe, D. Vanden, Maes, L., 2006. Anti-infective potential of natural products: How to develop a stronger *invitro* "proof-of-concept". Journal of Ethnopharmacology 106, 290–302.

Daniewski, W.M., Gumulka, M., Pankowska, E., 1994. Entilin C, a novel heptanortriterpenoid from *Entandrophragma utime* (Meliaceae). Polish Journal of Chemistry 68, 499–502.

Desjardins, R.E., Canfield, C.J., Haynes, J.D., Chulay, J.D., 1979. Quantitative assessment of antimalarial activity *invitro* by a semiautomated microdilution technique. Antimicrobial Agents and Chemotherapy 16, 710–718.

Douanla, P.D., Tabopda, T.K., Tchinda, A.T., Cieckiewicz, E., Freidrich, M., Boyom, F.F., Tsabang, N., Yeboah, S., Nkengfack, A.E., Tchuendem, M.H.K., 2015. Antrocarines A-F, antiplasmodial ergostane steroids from the stem bark of *Antrocaryon klaineanum*. Phytochemistry 117, 521–526.

Dzubak, P., Hajduch, M., Vydra, D., Hustova, A., Kvasnica, M., Biedermann, D., Markova, L., Urban, M., Sarek, J., 2006. Pharmacological activities of natural triterpenoids and their therapeutic implications. Natural Product Reports 23, 394–411.

Feusso, H.M.F., Akak, C.M., Tala, M.F., Azebaze, A.G.B., Tsabang, N., Vardamides, J.C., Laatsch, H., 2016. Conocarpol, a new cycloartane triterpenoid from *Diospyros conocarpa*. Zeitschrift für Naturforschung 71, 935–940.

Fongang, M.A.L., Nguemfo, E.L., Djouatsa, N.Y., Bogning, Z.C., Fouokeng, Y., Azebaze, A.G.B., Llorent-Martínez, J.E., Maria, L.F.C., Dongmo, B.A., Wolfgang, V., 2017. Antinociceptive and anti-inflammatory effects of the methanolic stem bark extract of *Antrocaryon klaineanum* Pierre (Anacardiaceae) in mice and rat. Journal of Ethnopharmacology 203, 11–19.

Fouokeng, Y., Akak, C.M., Tala, M.F., Azebaze, A.G.B., Dittrich, B., Vardamides, J.C., Laatsch, H., 2017. The structure of antrocarine E, an ergostane isolated from *Antrocaryon klaineanum* Pierre (Anacardiaceae). Fitoterapia 117, 61–64.

Freiburghaus, F., Jonker, S.A., Nkunya, M.H.H., Mwasumbi, L.B., Brun, R., 1997. *In vitro* trypanocidal activity of some rare tanzanian medicinal plants. Acta Tropica 66, 79–83.

Fujioka, T., Kashiwanda, Y., 1994. Anti-AIDS agents. Betullinic acid and platonic acid as anti-HIV principles from *syzigum claviflorum*, and the anti-HIV activity of structurally related triterpenoids. Journal of Natural Products 57, 243–247.

Ganapaty, S., Steve Thomas, P., Karagianis, G., Waterman, P.G., Brun, R., 2006. Antiprotozoal and cytotoxic naphthalene derivatives from *Diospyros assimilis*. Phytochemistry 67, 1950–1956.

Grobler, J.A., Stillmock, K., Hu, B., Witmer, M., Felock, P., Espeseth, A.S., Wolfe, A., Egbertson, M., Bourgeois, M., Melamed, J., Wai, J.S., Young, S., Vacca, J., Hazuda, D.J., 2002. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proceedings of the National Academy of Sciences of the United States of America 99, 6661–6666.

Guha, S., Ghosal, S., Chattopadhyay, U., 1996. Antitumor, immunomodulatory and anti-HIV effect of mangiferin, a naturally occurring glucosylxanthone. Chemotherapy 42, 443–451.

Kantamreddi, V.S.S., Wright, C.W., 2008. Investigation of Indian *Diospyros* species for antiplasmodial properties. Evidence-based Complementary and Alternative Medicine 5, 187–190.

Kémeuzé, V.A., Nkongmeneck, B., 2011. *Antrocaryon klaineanum* Pierre. In: Lemmens, R.H.M.J., Louppe, D., Oteng-Amoako, A.A. (Eds.), Prota 7(2): Timbers/ Bois d'œuvre 2. [CD-Rom]. PROTA. Wageningen, Netherlands, pp. 85–88.

Krettli, A.U., 2009. Antimalarial drug discovery: screening of Brazilian medicinal plants and purified compounds. Expert Opinion on Drug Discovery 4, 95–108.

Lin, Y.M., Anderson, H., Flavin, M.T., Pai, Y.H., Mata-Greenwood, E., Pengsuparp, T., Pezzuto, J.M., Schinazi, R.F., Hughes, S.H., Chen, F.C., 1997. *In vitro* anti-HIV activity of biflavonoids isolated from *Rhus succedanea* and *Garcinia multiflora*. Journal of Natural Products 60, 884–888.

Mallavadhani, U.V., Panda, A.K., Rao, Y.R., 1998. Pharmacology and chemotaxonomy of *Diospyros*. Phytochemistry 49, 901–951.

Maridass, M., 2008. Phytochemicals from genus *Diospyros* (L .) and their biological activities. Ethnobotanical Leaflets 12, 231–244.

Matig, O.E., Ndoye, O., Awono, A., 2006. Les fruitiers forestiers comestibles du Cameroun. IPGRI (Internonational Plant Genetic Ressources Institute) (204 p.).

Mayaux, J.F., Bousseau, A., Pauwels, R., Huet, T., Hénin, Y., Dereu, N., Evers, M., Soler, F., Poujade, C., De Clercq, E., 1994. Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells. Proceedings of the National Academy of Sciences of the United States of America 91, 3564–3568.

Modi, M., Nutan Pancholi, B., Kulshrestha, S., Rawat, A.K.S., Malhotra, S., Gupta, S.K., 2013. Anti-HIV-1 activity, protease inhibition and safety profile of extracts prepared from *Rhus parviflora*. BMC Complementary and Alternative Medicine 13, 158–166.

Mohamed, I.E., El Nur, E.B.E., Choudhary, M.I., Khan, S.N., 2009. Bioactive natural products from two sudanese medicinal plants *Diospyros mespiliformis* and *Croton zambesicus*. Records of Natural Products 3, 198–203.

Norhayati, I., Getha, K., Muhd Haffiz, J., Mohd Ilham, A., Lili Sahira, H., Siti Syarifah, M.M., Muhd Syamil, A., 2013. *In vitro* antitrypanosomal activity of Malaysian plants. Journal of Tropical Forest Science 25, 52–59.

Nunomura, R.C.S., Oliveira, V.G., Da Silva, S.L., Nunomura, S.M., 2009. Characterization of bergenin in *Endopleura uchi* bark and its anti-inflammatory activity. Journal of the Brazilian Chemical Society 20, 1060–1064.

Nwodo, N.J., Ibezim, A., Ntie-Kang, F., Adikwu, M.U., Mbah, C.J., 2015. Anti-trypanosomal activity of Nigerian plants and their constituents. Molecules 20, 7750–7771.

Pandey, K.K., Grandgenett, D.P., 2008. HIV-1 integrase strand transfer inhibitors: Novel insights into their mechanism of action. Retrovirology 2, 11–16.

Pathak, A., Kulshreshtha, D.K., Maurya, R., 2004. Coumaroyl triterpene lactone, phenolic and naphthalene glycoside from stem bark of *Diospyros angustifolia*. Phytochemistry 65, 2153–2158.

Pengsuparp, T., Cai, L., Fong, H.H.S., Kinghorn, A.D., Pezzuto, J.M., Wani, M.C., Wall, M.E., 1994. Pentacyclic triterpenes derived from *Maprounea africana* are potent inhibitors of HIV-1 reverse transcriptase. Journal of Natural Products 57, 415–418.

Prachayasittikul, S., Saraban, P., Cherdtrakulkiat, R., Ruchirawat, S., Prachayasittikul, V., 2010. New bioactive triterpenoids and antimalarial activity of *Diospyros rubra* Lec. EXCLI Journal 9, 1–10.

Roy, S., Dutta, A.K., Chakraborty, D.P., 1982. Amasterol, an ecdysone precursor and a growth inhibitor from *Amaranthus viridis*. Phytochemistry 21, 2417–2420.

Sahar, E.-M., Essam, A.-S., Masao, H., Kawahata, T., Otake, T., 2009. Screening of egyptian medicinal plant extracts for anti-human immunodeficiency virus. Screening of Medicinal Plants in Egypt Garden 1, 1–9.

Sima, O.C., Obame, E.L.-C., Ondo, J.-P., Zongo, C., Nsi, E.E., Alfred, T.S., 2015. Ethnotherapy study, phytochemical screening and antioxidant activity of *Antrocaryon klaineanum* Pierre and *Anthocleista nobilis* G. Don. medicinal plants from Gabon. International Journal of Advanced Research 3, 812–819.

Sinha, B.N., Bansal, S.K., 2008. A review of phytochemical and biological studies of *Diospyros* species used in folklore medicine of Jharkhand. Journal of Natural Remedies 8, 11–17.

Soh, P.N., Benoit-Vical, F., 2007. Are West African plants a source of future antimalarial drugs? Journal of Ethnopharmacology 114, 130–140.

Suedee, A., Tewtrakul, S., Panichayupakaranant, P., 2014. Anti-HIV-1 integrase activity of *Mimusops elengi* leaf extracts. Pharmaceutical Biology 52, 58–61.

Sutthivaiyakit, S., Seeka, C., Kritwinyu, T., Pisutchareonpong, S., Chimnoi, N., 2012. 19-nor-11-Oxooleanan-12-ene and 18,19-seco-19-oxours-11,13(18)-diene triterpenes from *Diospyros decandra* bark. Tetrahedron Letters 53, 1713–1716.

Tchouankeu, J.C., Tsamo, E., Sondengam, B.L., Connolly, J.D., Rycroft, D.S., 1990. Entilins A and B, two novel heptanortriterpenoid derivatives from *Entandrophragma utile* (Meliaceae): Structural elucidation using 2D NMRlong-range 13C/1H correlation experiments. Tetrahedron Letters 31, 4505–4508.

Tchouankeu, J.-C., Nyasse, B., Tsamo, E., Connolly, J.D., 1996. 7r,20(S)-Dihydroxy-4,24(28)-ergostadien-3-one from *Entandrophragma utile*. Journal of Natural Products 59, 958–959.

Venkateswara Rao, G., Sahoo, M.R., Madhavi, M.S.L., Mukhopadhyay, T., 2014. Phytoconstituents from the leaves and seeds of *Manilkara zapota* linn. Der Pharmacia Letter 6, 69–73.

Wellems, T.E., Plowe, C.V., 2001. Chloroquine-resistant malaria. Journal of Infectious Diseases 184, 770–776.

WHO, 2017. HIV/AIDS Fact sheet n°360. http://www.elsevier.com/xml/linking-roles/text/html.

Xu, H.X., Zeng, F.Q., Wan, M., Sim, K.Y., 1996. Anti-HIV triterpene acids from *Geum japonicum*. Journal of Natural Products 59, 643–645.

Yili, A., Mutalipu Aisa, H.A., Isaev, M.I., 2009. Betulinic acid and sterols from *Astragalus altaicus*. Chemistry of Natural Compounds 45, 592–594.

Zhu, L., Wu, J., Liao, H., Gao, J., Zhao, X.N., Zhang, Z.X., 1997. Antagonistic effects of extract from leaves of *ginkgo biloba* on glutamate neurotoxicity. Zhongguo Yao Li Xue Bao 18, 344–347.